Sign in to view content

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

Vrinda S. Hershberger, MD, PhD

Video
Published 2021

Related

Episode 198: Journal Club about Online Physician Reviews, Systematic Review Reliability, SCORE2 24 month Data, Brolucizumab FDA Approval
Jayanth Sridhar, MD
Member Podcasts
2019
Intravitreal Bevacizumab vs. Bevacizumab with Dexamethasone for the Treatment of Exudative Age-Related Macular Degeneration
Reda Issa, MD
On Demand Cases, Courses, and Papers
2019
Assessing Supplemental Injection Use Across Groups in the Phase 2 DAVIO 2 Trial of EYP-1901 vs Aflibercept in Wet Age-Related Macular Degeneration
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2024

Category: AMD-Neovascular

See more